95603-75-1

Upstream product

• 929-12-4 5-Acetoxy-2-methyl-2-pentene 
• 95603-72-8 Acetic acid (E)-5-hydroxy-4-methyl-pent-3-enyl ester 
• 95603-73-9 2-methyl-2-pentene-1,5-diol diacetate 
• 98320-66-2 (E)-4-Methyl-tridec-3-enoic acid methyl ester 
• 98320-65-1 methyl 7-tosyloxy-4-methyl-3-heptenoate 
• 98320-63-9 (E)-6-(3,3-Dimethyl-oxiranyl)-4-methyl-hex-3-enoic acid methyl ester 
• 98320-64-0 methyl 7-hydroxy-4-methyl-3-heptenoate 
• 106-24-1 Geraniol 
• 459-85-8 (E)-4,8-dimethylnona-3,7-dienoic acid 
• 21677-96-3 geranyl cyanide 
• 6138-90-5 trans-geranyl bromide 
• 95603-74-0 (E)-4-methyl-3-tridecen-1-ol 
• 98-59-9 p-toluenesulfonyl chloride 
• 19435-42-8 Methyl 4,8-Dimethylnona-3,7-dienoate 

Downstream Products

• 100992-30-1 (4E,8E,2S,3S,2'R)-N-2'-acetoxyhexadecanoyl-1-O-benzoyl-9-methyl-4,8,-sphingadienine 
• 100924-04-7 (4E,8E,2S,3R,2'R)-N-2'-acetoxyhexadecanoyl-1-O-benzoyl-9-methyl-4,8-sphingadienine 
• 88642-46-0 1-O-(β-D-glucopyranosyl)-(2S,3R,4E,8E)-2-[(2'R)-2'-(hydroxyhexadecanoyl)amido]-9-methyl-4,8-octadecadiene-1,3-diol 
• 100924-08-1 Benzoic acid (4E,8E)-(2S,3S)-2-amino-3-hydroxy-9-methyl-octadeca-4,8-dienyl ester; hydrochloride 
• 100933-62-8 1-O-benzoylsphingadienine*HCl 
• 100924-02-5 (2'E,6'E,4R,1'S)-4-(1'-hydroxy-7'-methyl-2',6'-hexadecadienyl)-2-phenyl-1,3-oxazolin-2-ene 
• 100924-01-4 (2'E,6'E,4S,1'R)-4-(1'-hydroxy-7'-methyl-2',6'-hexadecadienyl)-2-phenyl-1,3-oxazolin-2-ene 
• 100933-63-9 (4E,8E,2S,3R,2'R)-N-2'-hydroxyhexadecanoyl-1-O-(tetra-O-acetyl-β-D-glucopyranosyl)-3-O-(t-butyldiphenylsilyl)-9-methyl-4,8-sphingadienine 
• 100924-07-0 (4E,8E,2S,3R,2'R)-N-2'-hydroxyhexadecanoyl-1-O-β-D-glucopyranosyl-3-O-(t-butyldiphenylsilyl)-9-methyl-4,8-sphingadienine 
• 100924-05-8 (4E,8E,2S,3R,2'R)-N-2'-acetoxyhexadecanoyl-1-O-benzoyl-3-O-(t-butyldiphenylsilyl)-9-methyl-4,8-sphingadienine 
• 100924-06-9 (4E,8E,2S,3R,2'R)-N-2'-hydroxyhexadecanoyl-3-O-(t-butyldiphenylsilyl)-9-methyl-4,8-sphingadienine 

Relevant academic research and scientific papers

Novel aliphatic compounds, process for their preparation and their usage

The present invention provides an aliphatic compound represented by the following formula (I) or pharmacologically acceptable salts thereof: where n denotes an integer of 1 to 11, and 1 denotes an integer of 1 to 16, the aliphatic compound being an optical isomer of the (2R,3S,2′S) configuration when the 8-position thereof is a double bond, or an optical isomer of the (2S,3R,2′RS) configuration when the 8-position is a single bond; methods for producing the compound or pharmacologically acceptable salts thereof; and uses of the compound in the treatment of cardiovascular diseases (e.g. arteriosclerosis, cardiac diseases), cancer, rheumatism, diabetic retinopathy, and respiratory diseases.

SYNTHESIS OF (4E,8E,2S,3R,2'R)-N-2'-HYDROXYHEXADECANOYL-9-METHYL-4,8-SPHINGADIENINE, THE CERAMIDE PORTION OF THE FRUITING-INDUCING CEREBROSIDE IN A BASIDIOMYCETE SCHIZOPHYLLUM COMMUNE, AND ITS (2R,3S)-ISOMER

A synthesis of the natural enantiomer as well as its diastereomer of the title compound was accomplished, confirming the structure proposed for the fruiting-inducing cerebroside of Schizophyllum commune.

SYNTHESIS OF (4E,8E,2S,3R,2'R)-N-2'-HYDROXYHEXADECANOYL-1-O-β-D-GLUCOPYRANOSYL-9-METHYL-4,8-SPHINGADIENINE, THE FRUITING-INDUCING CEREBROSIDE IN A BASIDIOMYCETE SCHIZOPHYLLUM COMMUNE

The title compound was synthesized by employing (R)-2-aminohexadecanoic acid, D-glucose and (S)-serine as the chiral sources, and the synthetic sample was found to be chemically and biologically identical with the fruiting-inducing cerebroside isolated fr